Arguing that the Defense Department might have misread evidence and inflicted harm on the company, a federal judge has thrown WuXi AppTec a lifeline as the research and manufacturing services ...
As Alnylam’s Amvuttra sales disappointed, revenue from BridgeBio’s rival transthyretin amyloidosis (ATTR) drug Attruby came in above analysts’ expectations. | Despite their divergent second-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results